Concentrations of tenofovir and emtricitabine in saliva: Implications for preexposure prophylaxis of oral HIV acquisition

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4905-4907

  De Lastours, Victoire ^a   Fonsart, Julien ^a   Burlacu, Ruxandra ^a   Gourmel, Bernard ^a   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR; TIPRANAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SALIVA LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IC 50; MALE; ORAL SEXUAL CONTACT; PRIORITY JOURNAL; SALIVA ANALYSIS;

ADENINE; ADULT; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; SALIVA; SEXUAL BEHAVIOR;

EID: 80052833501     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00120-11     Document Type: Article

References (22)

1. Abdool Karim, Q., et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. Benaboud, S., et al. 2011. Breast milk concentrations of tenofovir and emtricitabine in HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS TEmAA Study, Step 2. Antimicrob. Agents Chemother. 55:1315-1317.
3. Blum, M. R., G. E. Chittick, J. A. Begley, and J. Zong. 2007. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J. Clin. Pharmacol. 47:751-759.
4. Brown, K. C., et al. 2011. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J. Infect. Dis. 203:1484-1490.
5. Byrd, G. D., R. A. Davis, and M. W. Ogden. 2005. A rapid LC-MS-MS method for the determination of nicotine and cotinine in serum and saliva samples from smokers: validation and comparison with a radioimmunoassay method. J. Chromatogr. Sci. 43:133-140.
6. Campo, J., et al. 2006. Oral transmission of HIV, reality or fiction? An update. Oral Dis. 12:219-228. (Pubitemid 43736411)
7. Delahunty, T., L. Bushman, and C. V. Fletcher. 2006. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830:6-12.
8. Delahunty, T., L. Bushman, B. Robbins, and C. V. Fletcher. 2009. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/ MS/MS and isotopically labeled internal standards. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:1907-1914.
9. Estrela Rde, C., et al. 2009. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 10:311-318.
10. Ghosn, J., et al. 2004. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18: 1958-1961. (Pubitemid 39313214)
11. Grant, R. M., et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
12. Kearney, B. P., J. F. Flaherty, and J. Shah. 2004. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43:595-612.
13. Kim, S. C., et al. 2010. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J. Int. AIDS Soc. 13:24.
14. Kiser, J. J., et al. 2008. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 52:631-637.
15. Le Saux, T., et al. 2008. Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 865:81-90.
16. Le Vu, S., et al. 2010. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect. Dis. 10:682-687.
17. Mullangi, R., S. Agrawal, and N. R. Srinivas. 2009. Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomed. Chromatogr. 23:3-25.
18. Rakhmanina, N. Y., et al. 2007. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther. Drug Monit. 29:110-117.
19. Robinson, E. K., and B. G. Evans. 1999. Oral sex and HIV transmission. AIDS 13:737-738.
20. Rothenberg, R. B., M. Scarlett, C. del Rio, D. Reznik, and C. O'Daniels. 1998. Oral transmission of HIV. AIDS 12:2095-2105. (Pubitemid 28495263)
21. Smink, B. E., et al. 2008. The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. Br. J. Clin. Pharmacol. 66:556-560.
22. Yeh, R. F., et al. 2009. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob. Agents Chemother. 53:2367-2374.